2022 Fall Conference | C26 - Treatment Approaches for Relapsing Multiple Sclerosis

Date Sunday 10/30/22

Time 09:30 AM - 11:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Carrie M. Hersh, DO, MSc, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be able to recognize different treatment strategies for relapsing multiple sclerosis (MS) when initiating and sequencing DMTs; discuss rationale for considering early highly effective and escalation therapeutic approaches: benefits, risks, and what is unknown; review real-world evidence using observational studies to support each approach; identify ongoing clinical trials assessing early treatment strategies for relapsing MS; and examine case-based scenarios that highlight different DMT approaches, including benefits and pitfalls.

CME Available 1.50 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials

Event Timeline
09:30 AM - 09:35 AM PDT	Introduction	Introduction Carrie M. Hersh, DO, MSc, FAAN
09:35 AM - 10:15 AM PDT	Speaker	Treatment Strategies for Multiple Sclerosis: What We Know and What We Don't Know Carrie M. Hersh, DO, MSc, FAAN
10:15 AM - 10:50 AM PDT	Speaker	Treatment Strategies for Multiple Sclerosis: Case-based Scenarios Le Hua, MD, FAAN
10:50 AM - 11:00 AM PDT	Q&A	Questions and Answers with Expert Panel Carrie M. Hersh, DO, MSc, FAAN, Le Hua, MD, FAAN

Faculty Disclosures
Carrie M. Hersh, DO, MSc, FAAN	Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech_GN41791. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb . Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Hersh has received research support from Biogen. The institution of Dr. Hersh has received research support from Novartis. The institution of Dr. Hersh has received research support from Genentech_GN41791. The institution of Dr. Hersh has received research support from PCORI. The institution of Dr. Hersh has received research support from Bristol Myers Squibb.
Le Hua, MD, FAAN	Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Hua has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hua has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hua has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Hua has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapuetics. The institution of Dr. Hua has received research support from Genentech.